The road to restore male fertility using in vitro-derived germ cells

Narrative review maps iPSC-to-sperm progress — validated precursor cells exist, but maturation to functional sperm remains unsolved

Journal: Human Reproduction Update | Published: 2026-03-01 | Type: Narrative Review | PMID: 41416641 Authors: Tiago Macedo, João Pedro Alves-Lopes (Department of Women's and Children's Health, Karolinska Institutet / Karolinska University Hospital) Funding/COI: Swedish Research Council (Starting Grant in Medicine and Health; WORK4ALL 2023 & 2024); Birgitta and Carl-Axel Rydbeck Research Grant 2024 | COI: not listed

Summary

This narrative review surveys efforts to derive functional male germ cells from human induced pluripotent stem cells (hiPSCs) — a potential route to biological fatherhood for men with no viable sperm. The field has matured enough to produce transcriptomically and epigenetically validated primordial germ cell-like cells (hPGCLCs), the earliest stage of germline commitment. The hard part — maturing those precursors into transplantable spermatogonial stem cells or functional sperm — remains largely unsolved, and no clinical application exists.

Claims

• Recent protocols reliably produce hPGCLCs validated against in vivo reference data using transcriptomics and epigenomics — a significant methodological advance over earlier, poorly characterized attempts
• hiPSCs derived from infertile men without underlying genetic syndromes generally retain the capacity for early germline commitment (hPGCLC specification)
• 3D culture systems are being developed to mimic the testicular microenvironment and push hPGCLCs toward more mature germline states
• Maturation of patient-derived cells beyond the hPGCLC stage is described as "limited" by the authors themselves
• No functional human sperm have been produced from hiPSCs; the review does not report any such outcome

Study Quality

This is a narrative review, not a systematic one — no registration number, no PRISMA framework, no formal risk-of-bias assessment. The authors searched PubMed, Scopus, and Web of Science with no time restriction, but selection of included studies was discretionary. That's standard for a field-mapping review, but it means the scope and emphasis reflect editorial judgment, not a reproducible protocol. The review appropriately limits its scope to male germline differentiation and flags animal studies rather than presenting them as human evidence. Human Reproduction Update is the field's flagship journal, which implies rigorous peer review, though that doesn't compensate for the inherent selection risk in narrative synthesis.

Red Flags

• Narrative review methodology allows authors to emphasize favorable results; no systematic bias assessment performed
• The abstract uses forward-looking language ("further breakthroughs... are likely to be achieved in the near future") that reads more like a grant pitch than a measured scientific assessment
• No actual clinical outcomes reported anywhere in this paper — this is entirely preclinical/translational
• Patient-derived cell maturation beyond hPGCLC stage is acknowledged as "limited," which is doing a lot of work given how far that is from clinical utility
• Ethical and regulatory frameworks for using lab-derived sperm in IVF do not yet exist in most jurisdictions — the review notes this but cannot resolve it

Strengths

• Karolinska group has direct research investment in this area, lending domain expertise to the synthesis
• Explicitly distinguishes early low-quality studies from recent, better-validated protocols — useful historiography
• Covers safety concerns (genomic stability of reprogrammed cells, epigenetic fidelity) rather than only technical progress
• Addresses ethical dimensions including equitable access, which most technical reviews skip
• Funding is public (Swedish Research Council), with no apparent industry entanglement

Verdict

This is a useful state-of-the-field map for researchers and science writers tracking reproductive medicine. It clearly communicates where the technology actually is — validated early-stage precursor cells in a dish — versus where advocates sometimes imply it is. The narrative format limits its evidential weight, and the optimistic framing in places outpaces what the evidence supports. For a curious reader: the science is genuinely progressing, no functional human sperm have been grown from stem cells, and clinical application remains hypothetical. Read it for orientation, not for findings.